Related Experiment Video
Updated: Nov 15, 2025
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
13.0K
[The CD40-CD40L axis: Current and future implications in clinical immunology].
G Vial1, N Gensous1, P Duffau2
1Department of Internal Medicine and Clinical Immunology, University Hospital Centre of Bordeaux, Saint-André Hospital, 33000 Bordeaux, France.
La Revue De Medecine Interne
|March 6, 2021
Summary
The CD40-CD40 ligand (CD40L) pathway is crucial in immune responses and diseases. Blocking CD40L with new therapies offers hope for managing autoimmune disorders and transplant rejection.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- The CD40-CD40 ligand (CD40L) pathway mediates immune cell communication.
- This pathway is implicated in autoimmune diseases, transplant rejection, and atherosclerosis.
- Dysregulation of CD40-CD40L signaling contributes to various pathologies.
Purpose of the Study:
- To review the clinical significance of the CD40-CD40L axis.
- To present current and emerging CD40L-blocking therapies.
- To highlight therapeutic strategies for dysimmune diseases.
Main Methods:
- Literature review of CD40-CD40L pathway research.
- Analysis of therapeutic antibody generations and their toxicities.
- Examination of drug impacts on CD40L levels.
Main Results:
- First-generation anti-CD40L antibodies showed thromboembolic toxicity.
- Newer antibody generations aim to mitigate toxicity for autoimmune diseases.
- Cardiology and immunology drugs may influence CD40L levels.
Conclusions:
- Targeting the CD40-CD40L axis is a key therapeutic strategy.
- Advancements in anti-CD40L therapies offer improved safety profiles.
- Clinicians may gain diverse options for managing immune-mediated diseases.
